Rare ovarian tumours. Other treatments for ovarian cancer by Marta Gil-Martin, Beatriz Pardo, Maria-Pilar Barretina-Ginesta

Get full text

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery by Andrea Plaja, Iris Teruel, Maria Ochoa-de-Olza, Marc Cucurull, Álvaro Javier Arroyo, Beatriz Pardo, Irene Ortiz, Marta Gil-Martin, Josep María Piulats, Helena Pla, Claudia Fina, Anna Carbó, Maria-Pilar Barretina-Ginesta, Sergio Martínez-Román, Elvira Carballas, Andrea González, Anna Esteve, Margarita Romeo

Get full text

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting by Margarita Romeo, Marta Gil-Martín, Lydia Gaba, Iris Teruel, Álvaro Taus, Claudia Fina, Maria Masvidal, Paola Murata, Julen Fernández-Plana, Alejandro Martínez, Cristina Pérez, Yolanda García, Valerie Rodriguez, Sara Cros, Marta Parera, Montserrat Zanui, Silvia Catot, Beatriz Pardo, Andrea Plaja, Anna Esteve, Maria Pilar Barretina-Ginesta

Get full text

638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study by Agostina Stradella, Francois Ghiringhelli, Ana Maia, Macarena Gonzalez, Cécile Gouttefangeas, Ulrich Herrlinger, David Reardon, Ahmed Idbaih, Patrick Wen, Ghazaleh Tabatabai, Wolfgang Wick, Mirjam Renovanz, Maria Vieito Villar, Christophe Bonny, Joao Gamelas Magalhaes, Hélène Toussaint, Jean-Michel Paillarse, Marta GilMartin, Iris Mildenberger, Michael C Burger, Alice Hervieu, Mehdi Touat, Antje Wick

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival w... by Hannah Woopen, Maren Keller, Dario Zocholl, Suzana Mittelstadt, Maria-Pilar Barretina-Ginesta, Viola Heinzelmann-Schwarz, Judith Lafleur, Roman Kocián, Joanna Baum, Petra Krabisch, Patriciu Achimas-Cadariu, Mehmet Ali Vardar, Ignace Vergote, Sara Nasser, Theresa Link, Marta Gil-Martin, Tibor A. Zwimpfer, Katharina Leitner, Marcin Jedryka, Tamara Boxler, Elena Ioana Braicu, Jalid Sehouli

Get full text

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors by Gabriel Capellá, Francisco X Real, Marta Gil-Martin, Rocio Garcia-Carbonero, Rafael Moreno, Ramon Alemany, Martí Farrera-Sal, Ramon Salazar, Teresa Macarulla, Jaime Martinez de Villarreal, Natalia del Pozo, Carmen Guillén-Ponce, Miriam Bazan-Peregrino, Rafael Álvarez, Ana Mato-Berciano, Emma Blasi, Carmen Blasco, Manel Cascallo, Maria C Riesco-Martinez, Helena Verdaguer, Maria Victoria Maliandi, Silvia Torres-Manjon, Marcel Costa, Noemí Vidal

Get full text

716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or ga... by Jean-Yves Blay, Antoine Italiano, Stephane Champiat, Paolo Antonio Ascierto, Manish Sharma, Jeeyun Lee, Luis Paz-Ares Rodriguez, Keun-Wook Lee, Yoon-Koo Kang, Drew Rasco, Edith A Perez, Mariano Ponz-Sarvise, Lu Xu, Jean-Philippe Spano, Coya Tapia, Ecaterina Dumbrava, Kathleen Moore, Jason Ptacek, Michele Magni, Alfonso Cortes Salgado, Ming Yin, Agnese Losurdo, Antoine Deleuze, Mark D Pegram, Ardaman Shergill, Alexander I Spira, Michael N Alonso, Joan Albanell Mestres, Marta GilMartin, Arielle Heeke, Ana Oaknin Benzaquen, Ignacio Ortego Zabalza, Haeseong Park, Cecile Vicier, Ivan Victoria, Benjamin Weinberg, Bob T Li